Abstract:Background To our knowledge, no randomised study has compared postmastectomy hypofractionated radiotherapy with conventional fractionated radiotherapy in patients with breast cancer. This study aimed to determine whether a 3-week schedule of postmastectomy hypofractionated radiotherapy is as efficacious and safe as a 5-week schedule of conventional fractionated radiotherapy. Methods This randomised, non-inferiority, open-label, phase 3 study was done in a single academic hospital in China. Patients aged 18-75 years who had undergone mastectomy and had at least four positive axillary lymph nodes or primary tumour stage T3-4 disease were eligible to participate. Patients were randomly assigned (1: 1) according to a computer-generated central randomisation schedule, without stratification, to receive chest wall and nodal irradiation at a dose of 50 Gy in 25 fractions over 5 weeks (conventional fractionated radiotherapy) or 43.5 Gy in 15 fractions over 3 weeks (hypofractionated radiotherapy). The modified intention-to-treat population (including all eligible patients who underwent randomisation but excluding those who were considered ineligible or withdrew consent after randomisation) was used in primary and safety analyses. The primary endpoint was 5-year locoregional recurrence, and a 5% margin was used to establish non-inferiority (equivalent to a hazard ratio <1.883). This trial is registered at ClinicalTrials.gov, number NCT00793962. Findings Between June 12, 2008, and June 16, 2016, 820 patients were enrolled and randomly assigned to the conventional fractionated radiotherapy group (n=414) or hypofractionated radiotherapy group (n=406). 409 participants in the conventional fractionated radiotherapy group and 401 participants in the hypofractionated radiotherapy group were included in the modified intention-to-treat analyses. At a median follow-up of 58.5 months (IQR 39.2-81.8), 60 (7%) patients had developed locoregional recurrence (31 patients in the hypofractionated radiotherapy group and 29 in the conventional fractionated radiotherapy group); the 5-year cumulative incidence of locoregional recurrence was 8.3% (90% CI 5.8-10.7) in the hypofractionated radiotherapy group and 8.1% (90% CI 5.4-10.6) in the conventional fractionated radiotherapy group (absolute difference 0.2%, 90% CI -3.0 to 2.6; hazard ratio 1.10, 90% CI 0.72 to 1.69; p< 0.0001 for non-inferiority). There were no significant differences between the groups in acute and late toxicities, except that fewer patients in the hypofractionated radiotherapy group had grade 3 acute skin toxicity than in the conventional fractionated radiotherapy group (14 [3%] of 401 patients vs 32 [8%] of 409 patients; p< 0.0001). Interpretation Postmastectomy hypofractionated radiotherapy was non-inferior to and had similar toxicities to conventional fractionated radiotherapy in patients with high-risk breast cancer. Hypofractionated radiotherapy could provide more convenient treatment and allow providers to treat more patients. Copyright (c) 2019 Elsevier Ltd. All rights reserved.

Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review

Systematic Review and Meta-Analysis Comparing Hypofractionated with Conventional Fraction Radiotherapy in Treatment of Early Breast Cancer

Hypo fractionated radiation therapy for breast cancer:A Meta analysis

Efficacy and Safety of Intraoperative Radiotherapy in Breast Conservative Surgery for Breast Cancer Patients: a Meta-Analysis

Safety and short-term efficacy analysis of breast-conserving surgery combined with intraoperative radiotherapy for early-stage breast cancer

Clinical trial of hypofractionation radiotherapy for early stage breast cancer after breast conserving surgery

Hypofractionated Versus Conventional Fractionated Postmastectomy Radiotherapy for Patients with High-Risk Breast Cancer: a Randomised, Non-Inferiority, Open-Label, Phase 3 Trial

Similar Outcomes of Standard Radiotherapy and Hypofractionated Radiotherapy Following Breast-Conserving Surgery.

Postmastectomy Hypofractionation Radiotherapy in High-Risk Breast Cancer Patients: A Phase Ⅰ/Ⅱ Clinical Trial

A Meta-Analysis of Clinical Trials Assessing the Effect of Radiofrequency Ablation for Breast Cancer.

Clinical Observation of Postoperative Hypofractionated Radiotherapy to Chest Wall in Breast Cancer

Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China

Postoperative complications of hypofractionated and conventional fractionated radiation therapy in patients with implant-based breast reconstruction: A systematic review and meta-analysis

Application of Biological Optimization of Hypofractionated Radiotherapy Post Conservative Surgery for Breast Cancer

A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose

Clinical analysis of efficacy results in 105 breast cancer patients treated with breast conserving surgery

Clinical efficacy and prognosis of adjuvant radiotherapy after breast-conserving surgery for stage I—II breast cancer

Efficacy and adverse effects of hypofractionated radiotherapy versus conventionally fractionated radiotherapy in patients with intermediate-to high-risk localized prostate cancer:a meta-analysis

Short-term efficacy of breast-conserving surgery plus intraoperative radiotherapy for early stage breast ;cancer

Lymphocyte Count Kinetics and the Effect of Different Radiotherapy Techniques on Radiation-Induced Lymphopenia in Patients with Breast Cancer Receiving Hypofractionated Postmastectomy Radiotherapy.